1. Introduction {#s0005}
===============

Since cognitive testing lacks the sensitivity required to detect the pre-symptomatic stages of LOAD, researchers continue to search for biomarkers of pre-MCI, MCI, and LOAD [@bb0005]. However, there currently are no validated biomarkers for the early detection of MCI or LOAD [@bb0010]. In the search for biomarkers of cognitive dysfunction it is essential for researchers to address the complex issue of patient heterogeneity in clinically defined MCI and LOAD patient populations [@bb0015], [@bb0020], [@bb0025]. Lipidomics is a powerful analytical platform that is being utilized to address this complexity [@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080], [@bb0085]. While a number of lipid alterations have been reported in LOAD, significant discrepancies between laboratories need to be resolved and a number of reported lipid changes require further validation. This literature has been reviewed a number of times but is restricted to LOAD with minimal available lipidomics data for MCI subjects [@bb0005], [@bb0030], [@bb0070], [@bb0075], [@bb0090], [@bb0095]. However, previous studies of LOAD have consistently demonstrated decrements in ethanolamine plasmalogen (PlsEs) levels in plasma [@bb0035], [@bb0040], [@bb0045], [@bb0050], [@bb0055] and brain [@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080] and increased levels of diacylglycerols (DAGs) in plasma [@bb0050], [@bb0055], [@bb0085] and brain [@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075]. Pilot studies of MCI plasma and brain also have detected elevated levels of DAGs [@bb0050], [@bb0055], suggesting a role early in the disease process. To extend these observations we performed a targeted high-resolution mass spectrometric analysis of plasma DAGs and PlsEs in larger cohorts of MCI and LOAD subjects.

2. Materials and methods {#s0010}
========================

2.1. Study participants {#s0015}
-----------------------

This study conforms to The Code of Ethics of the World Medical Association (Declaration of Helsinki) and was conducted accordingly to the guidelines for Good Clinical Practice (European Medicines Agency). Signed informed consent which was written in compliance with local and national ethical guidelines was obtained from each patient or from relatives or a legal guardian prior to patient inclusion in the study [@bb0100]. Cognitive function was evaluated with the Mini-Mental State Exam (MMSE) and the Babcock Story Recall Test (BSRT) [@bb0100], [@bb0105], [@bb0110], [@bb0115]. Serum was collected and stored at -80 °C for biochemical analyses.

2.2. Study participants: elderly controls ([Table 1](#t0005){ref-type="table"}) {#s0020}
-------------------------------------------------------------------------------

Elderly controls with no evidence of cognitive decline were included in the study.

2.3. Study participants: mild cognitive impairment (MCI, [Table 1](#t0005){ref-type="table"}) {#s0025}
---------------------------------------------------------------------------------------------

The diagnosis of MCI was made by trained geriatricians based on the presence of short/long-term memory impairment, with/without impairment in other single or multiple cognitive domains, in an individual who didn\'t meet the standardized criteria for dementia [@bb0110]. MMSE along with a battery of neuropsychological tests was used to evaluate the degree of cognitive impairment [@bb0115]. Patients with MCI due to known causes (e.g. depression, extensive white matter pathology, vitamin B12 deficiency) were excluded. Subjects affected by severe congestive heart failure (New York Heart Association class III-IV), severe liver or kidney disease, severe chronic obstructive pulmonary disease, and cancer, and those taking NSAIDS, antibiotics or steroids at the time of recruitment were also excluded. Only patients still independent in the activities of daily living (ADLs) were included in the study [@bb0100].

2.4. Study participants: late onset Alzheimer\'s Disease (LOAD, [Table 1](#t0005){ref-type="table"}) {#s0030}
----------------------------------------------------------------------------------------------------

A diagnosis of LOAD was made by trained geriatricians according to the NINCDS-ADRDA criteria [@bb0110]. All patients (controls, MCI, and LOAD) underwent a brain Computer Tomography (CT) scan at baseline performed with a third-generation scanner at 10 mm thickness (SOMATOM HQ, Siemens Healthcare, Milan, Italy). The CT information was used to support the clinical diagnosis and to diagnose possible brain pathologies associated with secondary cognitive impairment.

2.5. Lipid extraction and analysis {#s0035}
----------------------------------

Lipids were extracted from 100 μL of serum with methy-tert-butyl ether and methanol containing \[^2^H~8~\]arachidonic acid, \[^13^C~18~\]stearic acid, \[^13^C~3~\]DAG 36:2, \[^2^H~31~\]phosphatidylethanolamine 34:1, and bromocriptine as internal standards [@bb0050], [@bb0055], [@bb0110]. Extracts were dried by centrifugal vacuum evaporation and dissolved in isopropanol:methanol:chloroform (4:2:1) containing 15 mM ammonium acetate. Constant infusion lipidomics (5 μL per min) were performed utilizing high-resolution (140,000 at 200 amu; 0.2--2 ppm mass error) data acquisition [@bb0120], [@bb0125] on an orbitrap mass spectrometer (Thermo Q Exactive). The spray voltage was 3.3 kV, the sheath gas was 10, the capillary temperature was 320 °C, and the S lens RF was 50. Washes (500 μL) with methanol followed by hexane/ethyl acetate (3:2), between samples, were used to minimize ghost effects. In positive ion electrospray ionization (ESI), the ammonium adducts of diacylglycerols (DAG) were quantitated. The cation of bromocriptine was used to monitor for potential mass axis drift. Relative DAG levels were obtained by determining the ratio of the endogenous DAG peak area to the peak area of 1 nanomole if the internal standard \[^13^C~3~\]DAG 36:2. In negative ion ESI, the anions of phosphatidylethanolamines (PtdE) were quantitated. The anion of bromocriptine was used to monitor for potential mass axis drift. Relative PtdE levels were obtained by determining the ratio of the endogenous PtdE peak area to the peak area of 1 nanomole of the internal standard \[^2^H~31~\]PtdE 34:1.

2.6. Statistical analysis {#s0040}
-------------------------

R values (ratio of endogenous lipid peak area to the peak area of an appropriate internal standard) were calculated. Data are presented as mean ± SEM. Data were analyzed with the Kruskal--Wallis test, followed by the Dunn\'s t test to compare MCI and LOAD groups to the controls [@bb0050], [@bb0055].

3. Results and discussion {#s0045}
=========================

3.1. Diacylglycerols (DAGs) {#s0050}
---------------------------

For the current targeted lipidomics study we stratified the MCI and AD patient groups ([Table 1](#t0005){ref-type="table"}) based upon their Mini-Mental State Exam (MMSE) score as we have previously reported [@bb0050]. In addition, the Babcock Story Recall Test (BSRT) [@bb0100], [@bb0105] was utilized to support the MMSE scores with regard to evaluation of decline in cognitive function for individual patients ([Table 2](#t0010){ref-type="table"}). Utilizing this stratified design our targeted lipidomics analyses detected a number of DAGs that were elevated in the serum of MCI and LOAD patients as we [@bb0050], [@bb0055] and others [@bb0070] have previously reported. DAG 34:2 and DAG 36:2 were robust biomarkers being elevated in both MCI and LOAD patients with an MMSE score of 10 to 18 while DAG 36:2 also was elevated in MCI and LOAD patients with an MMSE score of 19 to 24 ([Table 2](#t0010){ref-type="table"}). Our previous studies have shown that DAG 34:2 is comprised mainly of DAG 16:0/18:2 while DAG 36:2 is 66% DAG 18:1/18:1 and 33% DAG 18:0/18:2, with no differences in fatty acid composition of these DAGs between aged-matched control, MCI and LOAD subjects [@bb0070]. Elevations in these lipid levels, which are normally tightly regulated [@bb0130], [@bb0135], is of significant clinical interest considering the diverse roles of DAGs as precursors of structural glycerophospholipids and neutral lipids, as structural components of nuclear and endoplasmic reticular membranes, as mediators of signal transduction, as mediators of nuclear signal transduction, and in Golgi transport carrier biogenesis [@bb0130], [@bb0135]. Alterations in any or all of these DAG-dependent functions could contribute to the development of neuronal dysfunction and ultimately to cognitive decline in MCI and LOAD patients.

3.2. Ethanolamine plasmalogens (PlsEs) {#s0055}
--------------------------------------

In the case of serum levels of PlsEs, PlsEs with polyunsaturated fatty acid substitutions were most dramatically affected in both MCI and LOAD patients, as we previously reported for LOAD patients [@bb0035], [@bb0040]. For example, PlsE 38:6 (16:0/22:6) was decreased in the MCI and LOAD cohorts with an MMSE in the range of 19 to 24 while PlsE 40:6 (18:0/22:6) were decreased in both MCI and both LOAD cohorts ([Table 2](#t0010){ref-type="table"}). The decrements in circulating plasmalogen levels monitored in the current study are in contrast with our previous negative findings in a smaller MCI patient cohort [@bb0050] and demonstrate the dangers of pilot biomarker evaluations in small patient cohorts. These data also support published observations of decreased peroxisomal function in the liver [@bb0140] and brain [@bb0145] of LOAD subjects and plasmalogen deficits in LOAD brain [@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080], further suggesting that peroxisomal dysfunction may occur early in the disease process in a subset of patients. Decrements in peroxisomal function and the resulting decreases in circulating and brain plasmalogens may represent a critical biochemical alteration that could lead to cognitive deficits. Plasmalogens are major components of membrane lipid rafts and are essential for neurotransmitter vesicular fusion [@bb0030], [@bb0150]. Alterations in these functions could result in both decreased acetylcholine release and altered postsynaptic signal transduction thereby negatively altering the function of cholinergic pathways involved in cognition [@bb0030].

3.3. Patient stratification {#s0060}
---------------------------

To further investigate potential heterogeneity within our patient cohorts, we calculated the percentage of patients with DAG levels greater than one standard deviation above the control group mean and the percentage of patients with PlsE levels more than one standard deviation below the control group mean ([Table 3](#t0015){ref-type="table"}). These analyses revealed that as would be expected: i) patient cohorts with the greatest cognitive deficit (MMSE of 10 to 18) had a larger number of patients with alterations in one of these lipid biomarkers relative to patients with less cognitive deficit (MMSE of 19 to 24) and ii) that there was a greater degree of heterogeneity in lipid alterations in the MCI cohorts relative to the LOAD cohorts. More significantly, we noted that when individual patients with elevated DAGs or decreased PlsEs were assessed there were no patients that possessed both lipid alterations ([Table 3](#t0015){ref-type="table"}). These data clearly demonstrate, at the biochemical level, that there are at least 3 potential subsets of patients within each of the clinical groups in our study: i) patients with lower circulating ethanolamine plasmalogen levels; ii) patients with augmented plasma DAG levels; and iii) patients with neither of these lipid alterations. However, these data do not preclude that analyses of an even larger patient cohort might identify patients possessing both elevated DAG and decreased PlsE levels. This caution is of significant clinical relevance since in our pilot study of a small patient cohort we only monitored an increase of DAG levels in MCI patients but failed to detect any patients with plasmalogen deficits [@bb0050], indicating that by chance, our patient cohorts failed to include any of the subset of patients with deficits in circulating ethanolamine plasmalogen levels. The potential role of ApoE phenotype in our observed lipid changes remains to be fully explored since the phenotype of patients in this study was not determined. However, previous studies of decreased circulating PlsEs [@bb0040] and increased plasma DAGs [@bb0050], [@bb0055] found no correlation with ApoE phenotype.

4. Conclusion {#s0065}
=============

These are exciting new observations which constitute initial efforts to define, at the biochemical level, the heterogeneity of disease processes that can ultimately result in cognitive impairment. Our observations may also be of value in the design of future clinical dementia trials. Inclusion of multiple biochemical parameters to define the heterogeneity of patient groups will aid in avoiding errors such as occurred in clinical evaluations of anti-amyloid therapies in dementia patients with no amyloid deposition [@bb0025]. Integration of lipidomics with other omics technologies has the potential to define different pathological mechanisms that lead to cognitive impairment and to distinguish patients at risk for dementia from [N]{.ul}on-[D]{.ul}emented individuals who possess significant [A]{.ul}lzheimer\'s Disease [N]{.ul}europathology (NDAN subjects) [@bb0155], [@bb0160], [@bb0165], [@bb0170], [@bb0175]. Ultimately lipidomics may offer an avenue to increase our understanding of the biochemical basis for the cognitive reserve or resistance factors in these NDAN subjects.

In summary, our data differentiate subsets of patients within clinically defined MCI and LOAD groups. The next steps will be to expand the investigation of these lipid biomarkers to larger patient cohorts which are monitored longitudinally with regard to both cognitive and lipidomics parameters, and ultimately brain pathology. Evaluation of these biochemical alterations in MCI and LOAD has the potential to define diverse biochemical pathologies that can ultimately lead to clinical cognitive deficits. Such analyses also will significantly contribute to defining new molecular targets for cognitive disorders and in the design of future therapeutic trials in dementia patients.

Author contributions {#s0070}
====================

PLW, CC, and GZ contributed to the design of the experiment, analysis of the data, and writing the manuscript. VL and PH conducted the lipidomics studies while AP, GBV, SV, and GV conducted patient evaluations and collection of serum. All authors have reviewed and approved the manuscript.

Competing Interests {#s0075}
===================

None.

Transparency document {#s0080}
=====================

Transparency document.

We thank the study participants and their families for their valuable contribution to aging and Alzheimer\'s research. This research was funded by Lincoln Memorial University, DeBusk College of Osteopathic Medicine, by "Ministero della Salute", IRCCS Research Program, Iccera Corrente 2012--2014, Linea n. 2 "Malattie complesse", and by the "5 × 1000" Voluntary Contribution.

The [Transparency document](http://dx.doi.org/10.1016/j.bbacli.2015.11.004){#ir0005} associated with this article can be found, in online version.

###### 

Patient demographics for the clinical cohorts.

  Parameter                   Controls      MCI-1          MCI-2          LOAD-1         LOAD-2
  --------------------------- ------------- -------------- -------------- -------------- --------------
  MMSE                        25--30        19--24         10--18         19--24         10--18
  N                           51            64             13             57             33
  Age                         76 ± 0.8      78.2 ± 0.062   77 ± 1.3       78 ± 0.7       78.2 ± 0.7
  Gender (% Male)             35.3          23.4           38.5           22.8           30.3
  Glucose (mg/dL)             95.3 ± 2.1    95.8 ± 1.5     93.4 ± 2.5     96.5 ± 2.5     95.3 ± 3.3
  Total Cholesterol (mg/dL)   207.4 ± 4.1   212.8 ± 4.4    210.8 ± 15.6   213.8 ± 4.7    218.3 ± 6.6
  HDL/LDL Ratio               0.55 ± 4.1    0.52 ± 0.022   0.44 ± 0.057   0.53 ± 0.023   0.51 ± 0.031
  Triglycerides (mg/dL)       109.9 ± 7.7   115.7 ± 6.4    150.4 ± 29.1   110.7 ± 6.0    110.5 ± 7.8

###### 

Mini-Mental Status Exam (MMSE) bracketed scores, Babcock Story Recall Test (BSRT) scores for memory, diacylglycerol (DAG) levels, and ethanolamine plasmalogen (PlsE) levels in control, Mild Cognitive Impairment (MCI), and Late Onset Alzheimer\'s Disease (LOAD) patients. The DAG and PlsE values are presented as the ratio (R) of the peak area of the endogenous lipid to the peak area of a stable isotope internal standard. Data are presented as mean ± SEM. \*, p \< 0.05 vs. control. \$, \[M + NH~4~\]^+^; \#, \[M--H\]^−^.

  Parameter                     Control       MCI-1           MCI-2           LOAD-1          LOAD-2
  ----------------------------- ------------- --------------- --------------- --------------- ---------------
  MMSE (bracketed range)        25--30        19--24          10--18          19--24          10--18
  BRST --- immediate (score)    5.1 ± 0.23    3.8 ± 0.29\*    4.3 ± 0.90      2.9 ± 0.32\*    2.2 ± 0.40\*
  BRST --- delayed (score)      6.0 ± 0.23    3.8 ± 0.34\*    2.3 ± 0.86\*    2.0 ± 0.30\*    1.0 ± 0.35\*
  DAG 34:2 (R) 610.54105^\$^    4.43 ± 0.22   5.04 ± 0.19     5.63 ± 0.32\*   5.00 ± 0.20     5.56 ± 0.42\*
  DAG 36:2 (R) 638.57235^\$^    2.77 ± 0.13   3.45 ± 0.12\*   3.94 ± 0.19\*   3.52 ± 0.12\*   3.84 ± 0.26\*
  PlsE 38:6 (R) 746.51301^\#^   2.66 ± 0.14   2.06 ± 0.12\*   1.97 ± 0.18     2.04 ± 0.11\*   2.11 ± 0.19
  PlsE 40:6 (R) 774.54431^\#^   2.17 ± 0.12   1.58 ± 0.10\*   1.41 ± 0.12\*   1.53 ± 0.09\*   1.51 ± 0.15\*

###### 

Demonstration of heterogeneity in the patient cohorts via analysis of subjects with DAG levels elevated more than one standard deviation above control values and subjects with ethanolamine plasmalogen (PlsE) levels decreased by more than one standard deviation below control values.

  Group    MMSE     ↑ DAG[1](#tf0005){ref-type="table-fn"}   ↓ PlsE[2](#tf0010){ref-type="table-fn"}   ↔ DAG or PlsE[3](#tf0015){ref-type="table-fn"}
  -------- -------- ---------------------------------------- ----------------------------------------- ------------------------------------------------
  MCI-1    19--24   25.5%                                    17.3%                                     57.2
  MCI-2    10--18   30.0%                                    45.1%                                     24.9
  LOAD-1   19--24   45.5%                                    29.6%                                     24.9
  LOAD-2   10--18   40.0%                                    44.8%                                     15.2

\% of group with DAG levels \> 1 SD above the control group levels.

\% of group with PlsE levels \> 1 SD below the control group levels.

\% of group with no increase in DAG or decrease in PlsE levels. There was no overlap between the subjects with elevated DAG levels and the subjects with lowered plasmalogen levels.
